Physician profile

Christopher J Higgins

Cardiovascular Disease · Tulsa, OK

NPI 1417123274

$12,633.05

in general payments reported to CMS, 2019-2025

41 companies · $1,076 in 2025

The $1,076 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Food and Beverage$4,725.57
Travel and Lodging$2,414.16

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Boston Scientific Corporation $2,923.03 2020-2025 Watchman Flx, Bodyguardian, Watchman
Medtronic, INC. $1,578.91 2021-2025 Abre, Hawkone, Resolute Onyx
Esperion Therapeutics, INC. $722.23 2020-2024 Nexletol
Abbott Laboratories $698.00 2019-2025 Mitraclip, Cardiomems, Esprit
Astrazeneca Pharmaceuticals LP $690.27 2019-2024 Farxiga, Brilinta
Abiomed $628.46 2023-2025 Impella
Medtronic Vascular, INC. $582.29 2019-2020
Angiodynamics, INC. $484.62 2021
Heartflow, INC. $409.51 2024
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $357.51 2019-2025 Lifevest
Novartis Pharmaceuticals Corporation $348.17 2019-2024
Edwards Lifesciences Corporation $339.99 2019-2024 Inspiris Resilia Aortic Valve, Sapien 3 Ultra Resilia
Merck Sharp & Dohme LLC $271.68 2021-2024 Verquvo
E.R. Squibb & Sons, L.L.C. $268.80 2019-2024 Eliquis, Camzyos
Amarin Pharma, INC. $252.43 2019-2022
Show all 41 companies
CompanyGeneral paymentsYearsTop products
Amgen INC. $240.42 2019-2023 Repatha
Cardinal Health 200 LLC $203.95 2019-2020
Cvrx, INC. $188.91 2021-2024 Barostim Neo System
Shockwave Medical, INC $172.80 2025
Terumo Medical Corporation $155.95 2021-2025 Heartrail, R2p Misago, Angio-Seal
Ge Healthcare $124.85 2024-2025
Teleflex LLC $105.39 2019-2022
Pfizer INC. $100.29 2019-2022
Sanofi-Aventis U.S. LLC $99.35 2019-2023
Kestra Medical Technology Services, INC. $95.70 2025 Assure Wcd
Janssen Pharmaceuticals, INC $93.25 2022-2023 Xarelto
Actelion Pharmaceuticals US, INC. $79.87 2022-2023 Opsumit
Inari Medical, INC. $78.92 2021-2023 Flowtriever Catheter, S, Ct Thrombectomy System Kit
Lexicon Pharmaceuticals, INC. $58.28 2023 Inpefa
Cardiovascular Systems INC. $43.28 2019
Zynex Medical, INC. $36.47 2025 Nexwave
Atricure, INC. $33.72 2024
Cordis US Corp. $31.58 2023-2024 Mynxgrip
Boehringer Ingelheim Pharmaceuticals, INC. $26.47 2019-2020
Scpharmaceuticals INC. $20.63 2024
Pacira Pharmaceuticals Incorporated $20.00 2022
Gilead Sciences, INC. $16.15 2019
Cook Medical LLC $15.36 2025 Icast Covered Stent System, 6mmx22mmx120cm
Chiesi USA, INC. $14.69 2020
Impulse Dynamics (USA) INC. $13.12 2023 Optimizer
Biomerieux INC $7.75 2019

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Christopher J Higgins

$12,633.05

in general payments reported 2019-2025

Years
2019-2025
Top company
Boston Scientific Corporation
Context
The $1,076 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).

https://glasscript.com/doctor/336105/christopher-j-higgins

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.